Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025

ASH Highlights and Clinical Translation

• Overview of recent medical advances presented at the ASH Annual Meeting
• Clinically relevant updates for hematology and oncology practice
• Disease-specific review of emerging treatment strategies
• Translation of research findings into practical patient care
• Approach to incorporating new evidence into treatment planning
• Review of emerging therapies and evolving standards of care
• Improving patient outcomes through timely access to new hematology data

Transplant Highlights

• ASH transplant highlights and major clinical updates
• Hematopoietic stem cell transplantation advances
• Patient selection and treatment strategy considerations
• New evidence affecting transplant decision-making
• Management issues related to transplant outcomes
• Integration of transplant data into hematologic malignancy care
• Practical review for clinicians involved in complex hematology care

ALL, CML and Myeloproliferative Neoplasms

• ASH highlights in acute lymphoblastic leukemia
• New and emerging treatment approaches in ALL
• Chronic myelogenous leukemia updates
• Myeloproliferative neoplasm highlights
• Clinical interpretation of new study data
• Therapeutic sequencing and treatment strategy considerations
• Applying ASH data to routine hematology practice

Classical Hematology Highlights

• ASH classical hematology updates
• New therapies and approaches in non-malignant hematology
• Coagulation disorder updates
• Clinical decision-making in complex blood disorders
• Practical interpretation of new classical hematology evidence
• Improving patient management using updated data
• Non-malignant hematology pearls for clinical practice

MDS and AML Updates

• Myelodysplastic syndrome highlights
• Acute myeloid leukemia updates from ASH
• Emerging treatment options in myeloid malignancies
• Risk stratification and therapeutic decision-making
• Interpreting new clinical trial data in MDS and AML
• Practical approaches to evolving treatment standards
• Clinical application of new evidence in leukemia care

CLL Highlights

• Chronic lymphocytic leukemia updates
• New data affecting CLL treatment strategies
• Approach to selecting therapies for CLL patients
• Emerging targeted therapies and treatment combinations
• Clinical interpretation of ASH CLL highlights
• Monitoring response and managing treatment-related issues
• Practical application of CLL updates in routine practice

Multiple Myeloma Highlights

• Multiple myeloma updates from ASH
• Emerging treatment strategies in plasma cell disorders
• New therapeutic approaches and clinical trial data
• Management considerations for relapsed and refractory disease
• Clinical interpretation of myeloma research highlights
• Integrating new therapies into patient-centered care
• Practical guidance for hematology and oncology clinicians

Lymphoma Highlights

• Lymphoma updates presented at ASH
• Hodgkin lymphoma and non-Hodgkin lymphoma highlights
• Emerging treatments in lymphoid malignancies
• New evidence affecting treatment selection
• Clinical data relevant to common lymphoma subtypes
• Approach to applying ASH lymphoma updates in practice
• Practical disease-specific review for clinicians managing lymphoma patients

CAR-T Highlights

• CAR-T therapy updates from ASH
• Emerging cellular therapy data
• Clinical applications of CAR-T in hematologic malignancies
• Patient selection and treatment strategy considerations
• Safety, toxicity, and outcome considerations in cellular therapy
• Integration of CAR-T data into lymphoma, leukemia, and myeloma care
• Future directions in cellular therapy and immune-based treatment

Waldenström’s Macroglobulinemia and Related Blood Disorders

• Updates in Waldenström’s macroglobulinemia
• Clinical interpretation of new plasma cell and lymphoplasmacytic disorder data
• Therapeutic considerations for rare hematologic malignancies
• Monitoring response and disease progression
• Practical management of complex blood cancer presentations
• Integrating emerging evidence into treatment planning
• Improving clinical confidence in less common hematologic disorders

This course is best suited for oncology and hematology physicians and trainees, primary care physicians, nurses, physician assistants, nurse practitioners, and clinicians caring for patients with hematologic disorders.

Topics include acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation, classical hematology, and CAR-T therapy.

Yes. The course is designed to highlight clinically relevant data and treatment updates presented at the ASH Annual Meeting.

Yes. The course focuses on disease-specific updates and emerging treatment approaches that can be applied in routine clinical practice.

Yes. This product is provided as recorded course access so you can review the material at your own pace.

No. CME credits and certificates are not included with this course package.

You can contact support at support@getmedicalcourses.com.